The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Association between an inflamed serum protein profile and outcomes in patients with LBCL
Sirpa Leppa, MD, PhD, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, discusses the findings of a study that analyzed serum proteome in patients with large B-cell lymphoma (LBCL) to characterize host response to lymphoma and to identify clinically relevant circulating proteins. The study also integrated circulating tumor DNA (ctDNA) data with the proteome. Overall, findings indicated that an inflamed serum protein profile was correlated with poor survival. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Consultancy; Pfizer: Consultancy; Orion Pharma: Consultancy; Bayer: Research Funding; BMS: Consultancy, Research Funding; Gilead Sciences: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Research Funding; Genmab: Research Funding; Nordic Nanovector: Research Funding.
